Lucentis (ranibizumab) plus laser treatment for DME raises bar for new therapies

A double blind Phase III trial in 691 patients has reported that 0.5mg Lucentis plus prompt or deferred laser therapy had a significant improvement in BCVA score compared to laser therapy alone (9 vs. 3 letters, p<0.001). The randomized trial, supported by Allergan and Genentech, compared ranibizumab plus prompt or deferred laser with triamcinoclone plus prompt laser for the treatment of diabetic macular edema (DME). As a result, Lucentis may become part of the standard of care for the treatment of DME and become incorporated into national treatment guidelines by the American Academy of Ophthalmology (AAO).